EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dual targeting macrophages and microglia is a therapeutic vulnerability in models of PTEN-deficient glioblastoma

Yang Liu, Junyan Wu, Hinda Najem, Yiyun Lin, Lizhi Pang, Fatima Khan, Fei Zhou, Heba Ali, Amy B Heimberger, Peiwen Chen

Journal of Clinical Investigation · 2024

DOI: 10.1172/jci178628 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2024. Verfasst von Yang Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Glioblastoma, PTEN Phosphohydrolase, Microglia, Protein-Lysine 6-Oxidase. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumor-associated macrophages and microglia (TAMs) are critical for tumor progression and therapy resistance in glioblastoma (GBM), a type of incurable brain cancer. We previously identified lysyl oxidase (LOX) and olfactomedin like-3 (OLFML3) as essential macrophage and microglia chemokines, respectively, in GBM. Here, single-cell transcriptomics and multiplex sequential immunofluorescence followed by functional studies demonstrate that macrophages negatively correlate with microglia in the GBM tumor microenvironment. LOX inhibition in PTEN -deficient GBM cells upregulates OLFML3 expression via the NF-κB-PATZ1 signaling pathway, inducing a compensatory increase of microglia infiltration. Dual targeting macrophages and microglia via inhibition of LOX and the CLOCK-OLFML3 axis generates potent antitumor effects and offers a complete tumor regression in more than 60% of animals when combined with anti-PD1 therapy in PTEN -deficient GBM mouse models. Thus, our findings provide a translational triple therapeutic strategy for this lethal disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaPTEN PhosphohydrolaseMicrogliaProtein-Lysine 6-OxidaseBrain NeoplasmsAnimalsMiceHumansMacrophagesTumor MicroenvironmentCell Line, TumorNeoplasm ProteinsSignal Transduction

Stichwörter der Autor:innen

Brain cancerCancer immunotherapyMacrophagesOncology

Substanzen

PTEN PhosphohydrolasePTEN protein, humanPten protein, mouseProtein-Lysine 6-OxidaseLOX protein, humanNeoplasm Proteins

Autor:innen und Institutionen

  • Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
  • Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Department of Genetics and.
  • UTHealth Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Case Comprehensive Cancer Center, Cleveland, Ohio, USA.

Förderung

  • NCI NIH HHS
  • NINDS NIH HHS

Zitieren

APA

Liu, Y., Wu, J., Najem, H., Lin, Y., Pang, L., Khan, F., Zhou, F., Ali, H., Heimberger, A. B., & Chen, P. (2024). Dual targeting macrophages and microglia is a therapeutic vulnerability in models of PTEN-deficient glioblastoma. Journal of Clinical Investigation. https://doi.org/10.1172/jci178628

Vancouver

Liu Y, Wu J, Najem H, Lin Y, Pang L, Khan F, et al. Dual targeting macrophages and microglia is a therapeutic vulnerability in models of PTEN-deficient glioblastoma. Journal of Clinical Investigation. 2024. doi:10.1172/jci178628

BibTeX
@article{Liu2024,
  author = {Liu, Yang and Wu, Junyan and Najem, Hinda and Lin, Yiyun and Pang, Lizhi and Khan, Fatima and Zhou, Fei and Ali, Heba and Heimberger, Amy B and Chen, Peiwen},
  title = {Dual targeting macrophages and microglia is a therapeutic vulnerability in models of PTEN-deficient glioblastoma},
  journal = {Journal of Clinical Investigation},
  year = {2024},
  doi = {10.1172/jci178628}
}
Kostenlos starten →